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OBJECTIVE: Assess the effect of patients’ out-of-pocket expen-
ditures (OOPE) on adherence and persistence with omalizumab
treatment for allergic asthma. METHODS: An incidence cohort
of asthma patients age 12 with 1 claim for omalizumab
during 2003–2006 and 6 months of prior insurance eligibility
was selected from a managed care claims database. Persistence
was determined using a survival analysis of the elapsed time
between ﬁrst omalizumab claim and omalizumab discontinua-
tion date (30 days after last omalizumab claim). Discontinuation
was deﬁned when >90 days elapsed between omalizumab claims.
Adherence was assessed in patients with 1 year of insurance
eligibility following ﬁrst omalizumab claim. Adherence was
deﬁned as the total “days supply” of omalizumab during the
one-year follow-up period. Proportional hazards models of per-
sistence and general linear regression models (log-linked gamma
distribution) of adherence estimated the impact of OOPE.
RESULTS: In the persistence cohort (N = 677), OOPE per oma-
lizumab claim was skewed to the right: average $105 ($175),
33rd percentile $25, median $40, 66th percentile $100. The
hazard ratio (HR) for discontinuing was 1.29 (95% CI: 1.05–
1.59) comparing patients with OOPE $100 vs <$00. Using the
bottom tertile as a reference, the HR for the top tertile was 1.31
(95% CI: 1.03–1.68) and the middle tertile was 1.03 (95% CI:
0.81–1.31). In the adherence cohort (N = 413), average OOPE
was $110 ($19), median $125 and average therapy days per
year was 216 (119). Adherence decreased with increasing
OOPE. Overall, the coefﬁcient on $1 of OOPE was -0.0004
(95% CI: -0.0007 to -0.0001), implying that an increase of $25
per claim would cause 1% therapy days lost for each patient.
CONCLUSION: Increasing patients’ OOPE may decrease adher-
ence and persistence with omalizumab. The effect on persistence
was signiﬁcant at higher levels of OOPE but not at lower levels.
The effect on adherence was small at the OOPE levels in this
insured population.
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OBJECTIVE: Three focus groups were conducted as a prelimi-
nary step in a broader initiative to develop a single compre-
hensive ASTHMA-CAT assessment that combines asthma
impact, asthma control, and generic health-related quality of life
(HRQOL) measures in one “seamless” administration, and dis-
plays results in tandem in a real-time patient feedback report.
METHODS: The sample included 22 English-speaking, non-
smoking adults (24–59 years) from the Boston area self-
reporting asthma (36% controlled, 27% somewhat controlled,
36% uncontrolled). Participants (64% women; 77% Caucasian,
18% African American, 5% Asian; 14% Hispanic) identiﬁed
areas of HRQOL impacted by asthma, and suggested content
and format revisions to a survey and feedback report. Focus
groups were taped and transcribed, and thematic content analy-
ses were conducted. RESULTS: Participants identiﬁed physical
(e.g., difﬁculty staying physically active, increased susceptibility
to secondary infection), social (e.g., avoiding places where there
may be environmental triggers), and emotional (e.g., anxiety or
worry; feeling a loss of control) aspects of health most impacted
by asthma. While participants generally reported that items
were clear and easy to understand, they noted content redun-
dancy, identiﬁed potential improvements to examples contained
within item stems, and indicated difﬁculty attributing health
impact solely to asthma. Participants were interested in feed-
back reports that showed their progress over time, with sufﬁ-
cient score interpretation, and saw value in sharing results with
their doctor. CONCLUSION: Focus group participants identi-
ﬁed core areas of HRQOL affected by asthma and provided
useful recommendations for improvements to survey content
and reporting features of the ASTHMA-CAT assessment. New
and revised item content will be evaluated in future quantitative
studies, and ﬁnal design features will be evaluated in usability
testing.
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OBJECTIVES: Uncertainty exists about the most meaningful
measure of health utilities for treatment comparisons, especially
for conditions with lower severity. This study explores these
issues for patients with allergic rhinitis (AR), which is a bother-
some and costly condition, but is not highly morbid. Inclusion
criteria for trials may select only patients with mild or moderate
symptom severity; furthermore, these patients often have access
to symptomatic medications. Consequently, discrimination of
treatment beneﬁt may be difﬁcult. METHODS: The study
reviews and compares the measurement properties of the EQ-5D
and SF-6D, with particular focus on their ability to discriminate
at lower levels of severity, a circumstance of AR. Data from
several studies of patients with AR demonstrate that a subset of
patients have severity of symptoms that can be meaningfully
captured with the EQ-5D (i.e., they are not at the ceiling), while
a large subset of patients have lower severity and may be better
assessed by the SF-6D. RESULTS: Several published studies of
patients with AR and data from this research team indicate that
the EQ-5D values are often at or near the ceiling (mean val-
ues  0.94), reﬂecting low symptom severity. Consequently, the
ability to discriminate and make meaningful resource allocations
may be compromised. Data from our naturalistic study found
that half of the patients with AR reported low symptom severity
(mean score of 1.3 on a scale from 0 to 3), suggesting that
EQ-5D values would be close to 1.0. CONCLUSIONS: For
conditions with lower overall severity and morbidity, such as
AR, using more than one utility measure may be informative.
The EQ-5D would provide more international comparability,
since it is the more generally accepted utility measure. However,
inclusion of another utility measure that can capture the lower
end of symptom severity may be a useful strategy for patients
with AR.
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